title: Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival.
abstract: Cholangiocarcinoma has historically represented a major contraindication to liver transplantation at many centers because of its high recurrence rate and low disease-free survival rate, even after radical surgery. Novel neoadjuvant therapy protocols combined with demolitive surgery and liver transplantation seem to achieve successful results in terms of overall and disease-free survivals. Surgery frequently seems to be unsatisfactory only for patients also suffering from chronic cirrhosis or end-stage liver disease. We have reported a case of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis treated with neoadjuvant radiochemotherapy and endoscopic brachytherapy, followed by liver transplantation combined with pancreatoduodenectomy, who has survived free of disease for >8 years.
authors.affiliation: Department of General Surgery and Organ Transplantation, Hepatobiliary Surgery and Liver Transplant Unit, University of Padova, Padova, Italy. enrico.gringeri@unipd.it
authors.forename: E
authors.initials: E
authors.lastname: Gringeri
authors.forename: D
authors.initials: D
authors.lastname: Bassi
authors.forename: F E
authors.initials: FE
authors.lastname: D'Amico
authors.forename: R
authors.initials: R
authors.lastname: Boetto
authors.forename: M
authors.initials: M
authors.lastname: Polacco
authors.forename: E
authors.initials: E
authors.lastname: Lodo
authors.forename: F
authors.initials: F
authors.lastname: D'Amico
authors.forename: A
authors.initials: A
authors.lastname: Vitale
authors.forename: P
authors.initials: P
authors.lastname: Boccagni
authors.forename: G
authors.initials: G
authors.lastname: Zanus
authors.forename: U
authors.initials: U
authors.lastname: Cillo
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001650:Bile Duct Neoplasms / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D001653:Bile Ducts, Intrahepatic / Q000473:pathology / Q000601:surgery*; D001918:Brachytherapy; D017024:Chemotherapy, Adjuvant; D018281:Cholangiocarcinoma / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D015209:Cholangitis, Sclerosing / Q000150:complications*; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006498:Hepatectomy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D016577:Pancreaticoduodenectomy; D018714:Radiotherapy, Adjuvant; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D007166:Immunosuppressive Agents; D005472:Fluorouracil; D016559:Tacrolimus